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ABSTRACT:
The  phosphatidylinositol  3-kinase  (PI3K)/Akt/mammalian  target  of  rapamycin 
(mTOR) signaling axis plays a central role in cell proliferation, growth, and survival 
under physiological conditions. However, aberrant PI3K/Akt/mTOR signaling has been 
implicated  in  many  human  cancers,  including  acute  myelogenous  leukemia  (AML). 
Therefore, the PI3K/Akt/mTOR network is considered as a validated target for innovative 
cancer therapy. The limit of acceptable toxicity for standard polychemotherapy has 
been reached in AML. Novel therapeutic strategies are therefore needed. This review 
highlights  how  the  PI3K/Akt/mTOR  signaling  axis  is  constitutively  active  in  AML 
patients, where it affects survival, proliferation, and drug-resistance of leukemic cells 
including leukemic stem cells. Effective targeting of this pathway with small molecule 
kinase inhibitors, employed alone or in combination with other drugs, could result in 
the suppression of leukemic cell growth. Furthermore, targeting the PI3K/Akt/mTOR 
signaling network with small pharmacological inhibitors, employed either alone or in 
combinations with other drugs, may result in less toxic and more efficacious treatment 
of AML patients. Efforts to exploit pharmacological inhibitors of the PI3K/Akt/mTOR 
cascade which show efficacy and safety in the clinical setting are now underway.
INTRODUCTION
Acute myelogenous leukemia (AML) is a highly het-
erogeneous group of malignant clonal diseases character-
ized  by  deregulated  proliferation  of  hematopoietic  stem 
cells and myeloid progenitors. This results in accumula-
tion, in the bone marrow, of myeloid cells with an impaired 
differentiation program and resistant to cell death. AML 
accounts for about 80% of adult leukemias and is a dis-
order of the elderly, with a median age at diagnosis of 65 
years and a growing incidence over 65 years [1]. Most 
AML cases respond well to initial polychemotherapy, but 
disease relapse occurs in the large majority of patients. The 
standard therapeutic approach for AML patients is high-
dose polychemotherapy, consisting of cytarabine and an 
anthracycline  antibiotic  like  daunorubicin  or  idarubicin, 
or the anthracendione mitoxantrone [2]. While results of 
AML treatment have improved in younger patients who 
can  tolerate  intensified  treatment  strategies,  there  have 
been limited changes in outcome among individuals who 
are older than 60 years. Therefore, the prognosis of AML 
remains severe, with an overall 5-year survival rate around 
20%,  despite  continuous  advances  in  our  understanding 
of AML biology. Furthermore, patients with AML arising 
out of myelodysplastic syndrome or who are older than 60 
years have an even worse prognosis (<10% survival at 5 
years) [3]. Therefore, there remains a need for innovative, 
rationally designed, minimally toxic, therapies for AML, 90
especially for the elderly [4]. 
Only one subtype of AML, acute promyelocytic leuke-
mia (APL), displays a much better prognosis, as differenti-
ation therapy with arsenic trioxide or all-trans retinoic acid 
(ATRA), used alone or in combination with chemothera-
peutic drugs, has proven quite successful in APL patients 
[5]. It is now clear that a hierarchical organization of the 
hematopoietic  system  does  exist  in AML,  as  in  normal 
hematopoiesis. Indeed, AML is initiated and maintained by 
a small, self-renewing population of leukemic stem cells 
(LSCs), which give rise to a progeny of more mature and 
highly cycling progenitors (colony forming unit-leukemia, 
CFU-L). CFU-Ls do not self-renew, however they are com-
mitted to proliferation and limited differentiation. By doing 
so, they originate a population of blast cells which consti-
tute the majority of leukemic cells in both the bone marrow 
and peripheral blood of patients. The exact phenotype of 
LSCs is still debated, but they are comprised in the CD34+/
CD38-/low population [6]. The majority of LSCs are quies-
cent and insensitive to traditional chemotherapeutic drugs. 
This latter feature explains, at least in part, the difficulties 
in eradicating this cell population by conventional poly-
chemotherapy. Thus, novel therapeutic strategies for AML 
eradication should also target LSCs [7]. In AML, aberrant 
activation of several signal transduction pathways strongly 
enhances the proliferation and survival of both LSCs and 
CFU-Ls  [8,  9].  Therefore,  these  signaling  networks  are 
attractive targets for the development of innovative thera-
peutic strategies in AML [10].
The phosphatidylinositol 3-kinase (PI3K, a family of 
lipid kinases)/Akt/mammalian target of rapamycin (mTOR) 
signaling  cascade  is  crucial  to  many  widely  divergent 
physiological processes which include cell cycle progres-
sion,  transcription,  translation,  differentiation,  apoptosis, 
Fig. 1.  The PI3K/Akt/mTOR signaling pathway. GPCRs, RTKs, and Ras activate PI3K. PI3K generates PtdIns (3,4,5)P3 from PtdIns (4,5)
P2. PtdIns (3,4,5)P3 attracts to the plasma membrane PDK1 which phosphorylates Akt on Thr308. Full Akt activation requires Ser473 phos-
phorylation which is effected by mTORC2. Most of the Akt substrates are inactivated by phosphorylation. Active Akt inhibits TSC2 activity 
through direct phosphorylation. TSC2 is a GAP that functions in association with TSC1 to inactivate the small G protein Rheb. Akt-driven 
TSC1/TSC2 complex inactivation allows Rheb to accumulate in a GTP-bound state. Rheb-GTP then activates the protein kinase activity 
of mTORC1. mTORC1 targets p70S6K and 4E-BP1 which are critical for translation. 4E-BP1 phosphorylation by mTORC1 results in the 
release of eIF4E, while p70S6K phosphorylates ribosomal S6 protein. The TSC1/2 complex is required to activate also mTORC2. However, 
other signaling cascades impinge on mTORC1, including GSK3β, the Ras/Raf/MEK/ERK1/2/p90RSK pathway, and the LKB1/AMPK network 
which is sensitive to the ADP/ATP ratio. Arrows indicate activating events, whereas perpendicular lines indicate inhibitory events. 
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motility,  and  metabolism  [11].  However,  the  PI3K/Akt/
mTOR signaling pathway represents one of the major sur-
vival pathways that is deregulated in many human cancers 
and contributes to both cancer pathogenesis and therapy 
resistance. Over the last few years, it has been reported 
that constitutive activation of the PI3K/Akt/mTOR signal-
ing network is a common feature of AML patients [12]. 
Furthermore,  pathway  activation  confers  leukemogenic 
potential to mouse hematopoietic cells [13]. Therefore, this 
signal transduction cascade may represent a valuable target 
for innovative therapeutic treatment of AML patients. The 
aim of this review is to give the reader an updated overview 
of the relevance of PI3K/Akt/mTOR signaling activation in 
AML patients and to focus on small molecules which will 
possibly have an impact on the therapeutic arsenal we have 
against this disease. 
The PI3K/Akt/mTOR pathway
PI3K
The family of PI3K enzymes is characterized by the 
ability to phosphorylate the 3’-OH group in inositol lipids 
and comprises three different classes, I, II, and III. Class 
I  PI3K  preferred  substrate  is  phosphatidylinositol  4,5 
bisphosphate [PtdIns (4,5)P2] which is phosphorylated to 
phosphatidylinositol 3,4,5 trisphosphate [PtdIns (3,4,5)P3] 
[14, 15]. PtdIns (3,4,5)P3 recruits to the plasma membrane 
pleckstrin  homology  (PH)  domain-containing  proteins, 
which include phosphoinositide-dependent protein kinase 
1 (PDK1) and Akt. Class I PI3K is divided further into A 
[activated by receptor tyrosine kinases (RTKs), Ras, and 
G-protein coupled receptors (GPCRs)] and B (activated by 
GPCRs) subtype (Figure 1). Class IA PI3Ks are heterodi-
meric  enzymes  composed  of  a  regulatory  (p85α,  p85β, 
p55α, p55γ, p50α) and of catalytic (p110α, p110β, p110δ) 
subunits. Class IB PI3K comprises a p101 regulatory and a 
p110γ catalytic subunit [16]. Both p110α and p110β PI3K 
play fundamental roles during development, so that their 
homozygous knockout is embryonic-lethal [17]. In con-
trast,  p110γ  and  p110δ  PI3Ks  are  mostly  related  to  the 
immune system functions, so that their knock-down leads 
to defective immune responses [18]. Class II PI3Ks, which 
comprise the PI3K-C2α, -C2β, and -C2γ isoforms, prefer-
entially phosphorylate phosphatidylinositol to yield phos-
phatidylinositol 3 phosphate. Although class II PI3Ks are 
widely expressed in mammalian organs and tissues, their 
relevance in cell signaling and cancer biology is not clear 
at the moment [19].
Vacuolar protein sorting 34 (vps34) is the only class III 
PI3K and exists as a heterodimer bound to the vps15 regu-
latory subunit (previously referred to as p150 in mammals). 
Vps34 has been implicated in nutrient signaling, endocyto-
sis, and autophagy [20].
Activating  mutations  in  the  gene  coding  for  p110α 
(PIK3CA) have been found in many human cancer types, 
including tumors of the colon, brain, ovary, breast, liver, 
and stomach, and could at least partially explain pathway 
up-regulation  in  these  neoplasms  [21].  Nevertheless,  in 
tumor  models  (brain,  prostate,  breast)  driven  by  PTEN 
(phosphatase and tensin homolog deleted on chromosome 
10) deficiency, knock-out of p110β, but not p110α, was 
required to inhibit Akt activation [17]. Wild-type p110α is 
not oncogenetic when overexpressed, whereas wild-type 
p110β,  p110γ,  and  p110δ  PI3Ks  are  oncogenetic  when 
ectopically expressed in chicken fibroblasts [22]. Neverthe-
less, their contribution to oncogenesis is only beginning to 
emerge [23].
Akt
Akt, a 57-kDa serine/threonine protein kinase, is the cel-
lular homolog of the v-akt oncogene. The Akt family com-
prises three highly conserved isoforms: Akt1/α, Akt2/β, and 
Akt3/γ, which display a high degree of sequence homology 
[14]. However, functional differences exist between Akt 
isoforms, as Akt2 is involved in insulin-mediated glucose 
uptake [24] and in cell motility/invasion/metastatic poten-
tial of cancer cells [25].
Akt contains an NH2-terminal PH domain, that interacts 
with PtdIns (3,4,5)P3. Once Akt is recruited at the plasma 
membrane, its activation loop is phosphorylated on Thr308 
by PDK1 while the mTOR complex 2 (mTORC2) phos-
phorylates Ser473 in the Akt COOH-terminus (Figure 1). 
Full Akt activation requires both the phosphorylation steps. 
Active Akt migrates to both the cytosol and the nucleus. 
Nuclear Akt may fulfil important anti-apoptotic roles [26]. 
Nevertheless, the relative contribution of Akt signaling at 
the plasma membrane, the cytosol, and the nucleus remains 
to be elucidated. However, it is intriguing that the protein 
promyelocytic leukemia (PML) is involved in the dephos-
phorylation of nuclear Akt as PML specifically recruits the 
Akt phosphatase, protein phosphatase 2A (PP2A), as well 
as phosphorylated Akt into PML nuclear bodies [27]. These 
bodies, however, are disrupted by the fusion protein, PML-
RARα, which is the hallmark of APL [5, 28]. This could be 
one of the reasons for Akt activation which is detected in 
APL [29]. Thus, this finding highlights the growing impor-
tance of Akt compartmentalization in human cancer patho-
genesis and treatment.
So far, over 100 Akt substrates have been identified 
[30].  Of  these,  about  40  which  mediate  the  pleiotropic 
Akt  functions  have  been  characterized,  including  Bad, 
caspase-9, murine double minute 2 (MDM2), IĸB kinase 
(IKK) α, proline-rich Akt substrate 40-kDa (PRAS40) 40, 
the FOXO family of Forkhead transcription factors, apop-
tosis signal-regulated kinase 1 [ASK1, a negative regula-
tor of pro-apoptotic c-Jun N-terminal kinase (JNK)], Raf, 
p27Kip1, p21Cip1, glycogen synthase kinase 3β (GSK3β. Each 
of these substrates has a key role in the regulation of cell 
survival  and  proliferation,  either  directly  or  through  an 
intermediary [16, 31]. A rare, oncogenetic, activating muta-
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tion (E17K) in the PH domain of Akt1 has been detected 
in some types of solid cancers (breast, colon, ovary). This 
mutation resulted in Akt constitutive binding to the plasma 
membrane and was leukemogenic in mice [32]. 
mTOR
mTOR is an atypical 289-kDa serine/threonine kinase, 
originally identified in the yeast Saccharomyces Cerevi-
siae, that belongs to the PI3K-related kinase family and 
displays a COOH-terminal catalytic domain with a high 
sequence  homology  to  PI3K  (Figure  2).  This  similar-
ity could explain the cross-inhibition of mTOR by drugs 
which target PI3K (see below) [33]. mTOR signaling is 
conserved in eukaryotes from plants and yeasts to mam-
mals. mTOR exists as two complexes, referred to as mTOR 
complex 1 (mTORC1) and mTORC2. mTORC1 is com-
prised of mTOR/Raptor/mLST8/PRAS40/FKBP38/Deptor 
and is sensitive to rapamycin and its derivatives (rapalogs). 
mTORC2  is  composed  of  mTOR/Rictor/mLST8/SIN1/
Protor/Deptor and is generally described as being insensi-
tive to rapamycin/rapalogs, although long-term treatment 
of about 20% of cancer cell lines with rapamycin/rapa-
logs leads to dissociation of mTORC2 [34, 35]. mTORC1 
signaling integrates environmental clues (growth factors, 
hormones, nutrients, stressors) and information from the 
cell  metabolic  status.  Thus,  mTORC1  controls  anabolic 
processes for promoting protein synthesis and cell growth 
[36]. mTORC1 regulates translation in response to nutri-
ents/growth  factors  by  phosphorylating  components  of 
the protein synthesis machinery, including p70S6 kinase 
(p70S6K) and eukaryotic initiation factor 4E-binding pro-
tein 1 (4E-BP1). p70S6K phosphorylates the 40S ribosomal 
protein, S6, leading to active translation of mRNAs, while 
4E-BP1 phosphorylation by mTORC1 on several amino 
acidic residues (Ser37; Thr46; Ser65; Thr70) results in the 
release of the eukaryotic initiation factor 4E (eIF4E). eIF4E 
is a key component for translation of 5’ capped mRNAs, 
which include transcripts encoding growth promoting mol-
ecules, such as c-Myc, cyclin D1, cyclin-dependent kinase 
2, retinoblastoma protein, p27Kip1, vascular endothelial 
growth  factor  (VEGF),  and  signal  activator  and  trans-
ducer of transcription 3 (STAT3) [34, 37]. Furthermore, 
mTORC1 negatively regulates autophagy, a non-apoptotic 
form of cell death, which is attracting much attention, as it 
could affect sensitivity of tumors (including leukemias) to 
various forms of therapy [38].
Akt-mediated regulation of mTORC1 activity involves 
several mechanisms. Akt inhibits TSC2 (Tuberous Scle-
rosis 2 or hamartin) function through direct phosphoryla-
tion. TSC2 is a GTPase-activating protein (GAP) which 
associates  with TSC1  (Tuberous  Sclerosis  1  or  tuberin) 
for inactivating the small G protein Rheb (Ras homolog 
enriched in brain). TSC2 phosphorylation by Akt represses 
GAP activity of the TSC1/TSC2 complex, allowing Rheb 
to accumulate in a GTP-bound state. The mechanism by 
which Rheb-GTP activates mTORC1 has not been fully 
elucidated yet, although Rheb requires to be farnesylated 
for activating mTORC1 [39]. Thus, it could be inhibited by 
farnesyl-trasferase inhibitors (FTIs). Akt also phosphory-
lates  PRAS40,  an  inhibitor  of  the  interactions  between 
mTORC1  and  its  substrates,  and  by  doing  so,  prevents 
PRAS40  ability  to  suppress  mTORC1  signaling  [40]. 
Moreover, PRAS40 is a substrate of mTORC1 itself, and it 
has been demonstrated that mTORC1-mediated phosphor-
ylation of PRAS40 facilitates the removal of its inhibition 
on mTORC1 [41].
Moreover,  Ras/Raf/mitogen-activated  protein  kinase 
kinase (MEK)/extracellular signal-regulated kinase (ERK) 
1/2  signaling  positively  regulates  mTORC1  activity,  as 
both ERK 1/2 and p90 ribosomal S6 kinase (p90RSK) phos-
Fig. 2.  A schematic presentation of mTOR structure. Some of the proteins interacting with mTOR domains are highlighted. 
The FRB domain is where the FKBP12 and rapamycin complex binds which is within the region that binds FKBP38. 
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phorylate TSC2, thus suppressing its inhibitory function 
on Rheb [42] (Figure 1). mTORC1 signal transduction is 
inhibited by the master metabolic regulator, energy-sensing 
AMP-dependent protein kinase (AMPK), given that AMPK 
phosphorylates and activates TSC2 [43]. 
The  mechanisms  for  mTORC2  regulation  have  only 
begun  to  be  revealed.  However,  mTORC2  activation 
requires PI3K and the TSC1/TSC2 complex, but is inde-
pendent of Rheb and is largely insensitive to either nutrients 
or energy conditions [44]. mTORC2 phosphorylates Akt on 
Ser473 which enhances subsequent Akt phosphorylation 
on Thr308 by PDK1 [45]. Moreover, mTORC2 plays a role 
in cytoskeleton organization by controlling actin polymer-
ization [46] and phosphorylates protein kinase C (PKC) α 
[44]. Another down-stream target of mTORC2 is serum- 
and glucocorticoid-induced protein kinase 1 (SGK1) [47]. 
The oncogenetic role of mTORC2 has been recently high-
lighted by an investigation that documented the importance 
of mTORC2 in the development and progression of pros-
tate cancers induced in mice by PTEN loss [48].
Akt and mTORC1/2 are linked to each other via posi-
tive  and  negative  regulatory  feedback  circuits,  which 
restrain their simultaneous hyperactivation through mech-
anisms which involve p70S6K and PI3K. Assuming that 
an  equilibrium  exists  between  mTORC1  and  mTORC2, 
when mTORC1 is formed, it antagonizes the formation of 
mTORC2 and reduces Akt activity. Indeed, once mTORC1 
is activated through Akt, the former elicits a negative feed-
back loop for inhibiting Akt activity [34]. This negative 
regulation of Akt activity by mTORC1 is a consequence 
of p70S6K-mediated phosphorylation of insulin receptor 
substrate  (IRS)  1  adapter  protein,  downstream  of  insu-
lin  receptor  and/or  Insulin-like  Growth  Factor-1  Recep-
tor (IGF-1R) [49, 50]. Indeed, IRS-1 phosphorylation on 
Ser307  and  Ser636/639  by  p70S6K  targets  the  adapter 
protein to proteasomal degradation [51]. Therefore, at least 
in principle, inhibition of mTORC1 activity by rapamy-
cin/rapalogs could result in hyperactivation of both Akt 
and its downstream targets. Such a phenomenon has been 
documented to occur both in vitro and in vivo [52, 53]. 
mTORC1 is capable of downregulating also IRS2 expres-
sion by enhancing its proteosomal degradation [54]. Con-
sistently,  mTORC1  inhibition  by  the  rapalog,  RAD001, 
increased IRS2 expression and Akt phosphorylation levels 
in AML  cells  [55].  Recent  work  has  also  highlighted  a 
p70S6K-mediated phosphorylation of Rictor on Thr1135. 
This phosphorylation event exerted a negative regulatory 
effect on the mTORC2-dependent phosphorylation of Akt 
in vivo [56]. Thus, both mTORC1 and mTORC2 control 
Akt activation. 
Nevertheless, the extent to which disruption of negative 
feedbacks mechanism actually limits the therapeutic effects 
of mTOR inhibitors in cancer patients in vivo remains to be 
determined [57].
Negative regulation of PI3K/Akt/mTOR signaling
A tight counter-regulation by phosphatases has emerged 
as a crucial process to control PI3K/Akt/mTOR-dependent 
signaling. PTEN is a dual specificity lipid/protein phospha-
tase that preferentially removes the 3’-phosphate mainly 
from PtdIns (3,4,5)P3 but is also active on phosphatidylino-
sitol  3,4  bisphosphate  [PtdIns  (3,4)P2],  thereby  antago-
nizing  network  signaling  [58,  59].  PTEN  silencing  or 
inactivating mutations have been detected in a wide variety 
of human neoplasias (including prostatic and endometrium 
carcinomas,  glioblastomas,  melanoma,  and  T-cell  acute 
lymphoblastic leukemia [60]) and this results in Akt/mTOR 
up-regulation.  SHIP-1  and  SHIP-2  (for  Src  homology 
domain-containing inositol phosphatase) are phosphatases 
capable of removing the 5-phosphate from PtdIns (3,4,5)P3 
to yield PtdIns (3,4)P2 [61]. An important role for SHIP-1 
in normal hematopoiesis has been recently described [62, 
63]. PP2A, which is now considered to be an oncosuppres-
sor, down-regulates Akt activity, through dephosphoryla-
tion of Thr308 [64]. Thr308 and Ser473 residues of Akt are 
also targeted by the two isoforms (1 and 2) of PH domain 
leucine-rich repeat protein phosphatase (PHLPP) [65].
Activation of PI3K/Akt/mTOR signals in AML
From 50% to 80% of patients with AML display Akt 
phosphorylated on either Thr308 or Ser473 (or both) [66-
71]. Both the disease-free survival and the overall survival 
were significantly shorter in AML cases where pathway 
up-regulation was documented [70, 72-74]. Poor prognosis 
of AML patients with elevated PI3K/Akt/mTOR signal-
ing could be also related to the fact that this pathway con-
trols the expression of the membrane ATP-binding cassette 
(ABC) transporter, multidrug resistance-associated protein 
1, which extrudes chemotherapeutic drugs from leukemic 
cells and is usually associated with a lower survival rate 
[75, 76].
Nevertheless, a more recent report has highlighted that 
constitutive activation of PI3K/Akt/mTOR signaling could 
be a favourable prognostic factor in de novo cases of AML. 
One hypothesis for the lower relapse rate in patients with 
enhanced PI3K/Akt/mTOR signaling is that it could drive 
immature leukemic cells (LSCs and CFU-L) into S phase, 
thus rendering them more susceptible to polychemotherapy 
[77]. 
Causes of PI3K/Akt/mTOR signaling up-regulation in 
AML may be the result of several factors, including activat-
ing mutations of Fms-like tyrosine kinase 3 (FLT3) receptor 
[71] and c-Kit tyrosine kinase receptor [78], N- or K-Ras 
mutations [79], PI3K p110β and/or δ overexpression [80-
82], low levels of PP2A [70], autocrine/paracrine secretion 
of growth factors such as IGF-1 [82-84] and VEGF [85, 
86]. Overexpression of PDK1 has been reported in 45% 
of a cohort of 66 AML patients, however it was related to 
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PKC hyperphosphorylation, while the relationship (if any) 
with Thr308 Akt up-regulation was not investigated [87]. 
Interactions between leukemic cells and bone marrow stro-
mal cells through CXCR4  (a GPCR which is abundantly 
expressed on leukemic cell surface where it is up-regulated 
by hypoxic conditions [88, 89]) and its physiological ligand, 
CXCL12, produced by stromal cells [89, 90], could result 
in PI3K/Akt/mTOR activation [91]. Furthermore, interac-
tions between β1 integrins on AML cells and stromal fibro-
nectin could lead to pathway activation [92, 93], possibly 
through up-regulation of integrin-linked kinase 1 (ILK1) 
which is involved in Akt phosphorylation on Ser473 in a 
PI3K-dependent manner in AML cells [94]. The ability of 
ILK1 to function as a Ser473 Akt kinase could be related to 
the fact that ILK1 interacted with Rictor and was required 
for Akt phosphorylation by mTORC2 on Ser473 [95]. Pos-
sible causes of pathway activation in AML cells are high-
lighted in Figure 3.
No activating mutations in p110α PI3K [96] or Akt1 
PH domain [70, 97] have been detected so far in AML 
patients. Although PTEN is deleted in many solid cancers 
and T-cell acute lymphoblastic leukemia, PTEN deletion 
is extremely rare in AML [66, 69, 70]. PTEN can be inac-
tivated by post-translational mechanisms, including phos-
phorylation  at  the  COOH-terminal  regulatory  domain. 
This phosphorylative event stabilizes PTEN molecule but 
makes it less active towards PtdIns (3,4,5)P3, thus resulting 
in Akt up-regulation [98]. PTEN phosphorylation has been 
reported in AML patients where it was significantly associ-
ated with high levels of p-Akt and with shorter overall sur-
vival [99]. However, subsequent studies could not confirm 
these findings [70, 74]. A reassessment of the PTEN role in 
AML could be important, as in mice, hematopoietic stem 
cells without functional PTEN, began multiplying rapidly, 
showed diminished self-renewal capacity, and started to 
move out of the bone marrow, colonizing distant organs, 
and originating a leukemic-like disease [100, 101]. Of note, 
these effects were mostly mediated by mTOR, as rapamy-
cin not only depleted LSCs, but also restored normal hema-
topoietic stem cell function [101].
It is conceivable that several concomitant extrinsic and 
intrinsic causes converge to activate PI3K/Akt/mTOR sig-
naling in AML patients, even if this fundamental issue has 
not been thoroughly investigated. Indeed, in the only pub-
lished study, it was demonstrated that, in a small cohort of 
patients, overexpression of PI3K p110δ [81] could coexist 
with activating FLT3 and Ras mutations. It has also been 
reported that mTORC1 activation was independent of PI3K/
Fig. 3. Constitutive activation of PI3K/Akt signaling in AML cells. In this cartoon, mutated (Mut) C-Kit, FLT3, or Ras, 
and autocrine/paracrine secretion of growth factors (VEGF, IGF-1) impinge upon increased levels of p110β and/or 
p110δ PI3K. This results in high levels of PtdIns (3,4,5)P3 synthesized at the plasma membrane from PtdIns (4,5)P2. 
PtdIns (3,4,5)P3 recruits at the plasma membrane both PDK1 and inactive Akt (Akt off). PDK1 phoshorylates Akt on 
Thr308, whereas phosphorylation on Ser473 is driven by mTORC2. These two phosphorylative events fully activates 
Akt (Akt on). Bone marrow stromal cells secrete CXCL12 and fibronectin. Fibronectin, by interacting with β integrins, 
could activate ILK which, in turn, stimulates mTORC2 activity on Ser473 Akt. CXCL12 binds its receptor CXCR4, 
a GPCR which results in increased PI3K activity. Bone marrow stromal cells could also secrete VEGF and IGF-1. 
Activated Akt migrates to both nucleus and cytosol to phosphorylate its substrates. 
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Akt activity in AML patients [55]. In some AML cases, it 
has been documented that either MEK/ERK 1/2 [102] or 
Lyn signaling [103] could be up-stream of mTORC1. TSC2 
gene expression was found to be down-regulated in AML 
patients,  most  likely  due  to  promoter  hypermethylation. 
However, it is not known if it impinged on mTORC1 acti-
vation [104].
It should be emphasized here that PI3K/Akt/mTOR net-
work up-regulation has been detected not only in the bulk of 
the AML blasts, but also in LSCs transplanted in non-obese 
diabetic/severe combined immunodeficiency (NOD/SCID) 
mice, where it exerted a powerful pro-survival effect. This 
finding suggests that therapeutic targeting of this pathway 
has the potential for eradicating AML [105]. 
Targeting PI3K/Akt/mTOR module in AML
Either used alone or in combination with other drugs, 
PI3K/Akt/mTOR  signaling  inhibitors  have  been  proven 
useful for down-regulating cell proliferation and inducing 
apoptosis in pre-clinical settings of AML, using cell lines 
or animal models. However, clinical trials of these com-
pounds  are  limited. We  shall  now  highlight  some  com-
pounds  which  have  been  used  for  targeting  PI3K/Akt/
mTOR signaling in AML cells.
PI3K inhibitors
Wortmannin and LY294002 are the best characterized 
PI3K inhibitors that have been widely used as research 
tools to elucidate the role of PI3K/Akt/mTOR signaling 
in various tumor cells. Both inhibitors are cell-permeable 
and low molecular weight compounds. Wortmannin is a 
natural metabolite produced by Penicillium wortmanni and 
inhibits all class PI3K members with a 50% inhibitory con-
centration (IC50) in vitro of 2-5 nM, while inhibiting other 
kinases  [mTOR,  DNA-dependent  protein  kinase  (DNA-
PK), and ataxia telangiectasia mutated kinase] with higher 
IC50 values [106]. It is interesting that DNA-PK was found 
to phosphorylate Akt on Ser473 under conditions of DNA 
damage [107].
LY294002 is a flavonoid-based synthetic compound and 
inhibits PI3K with an IC50 of 1-20 μM. However, LY294002 
blocks not only PI3K activity but also mTOR, DNA-PK, 
Pim kinase, polo-like kinase, and CK2 to the same extent 
as PI3K [106]. Both wortmannin and LY294002 bind to 
the p110 catalytic subunit of PI3K, leading to the blockade 
of ATP bound to the active portion. PI3K inhibition with 
LY294002 is reversible and ATP-competitive while wort-
mannin irreversibly inhibits PI3K in a non-ATP-competi-
tive manner [106]. 
Wortmannin  and  LY294002  have  been  used  in  pre-
clinical models of AML where they displayed powerful 
cytotoxic effects in vitro [66, 79, 108, 109]. Since the insol-
ubility in aqueous solutions and high toxicity of both inhib-
itors precluded their clinical application, efforts to develop 
PI3K inhibitors more suitable for clinical use are currently 
underway [110]. 
Several selective inhibitors of p110 PI3K isoforms are 
now available [111]. IC87114 is a compound that selec-
tively inhibits the p110δ isoform of PI3K. IC87114 down-
regulated p-Akt and p-FOXO3a, reduced proliferation, and 
induced apoptosis in AML primary cells overexpressing 
p110δPI3K. Moreover, it synergized with etoposide [81]. 
In primary APL cells, both IC87114 and TGX-115 (a p110β 
PI3K-selective inhibitor) triggered apoptosis in the pres-
ence or in the absence of the differentiating agent, ATRA 
[29]. 
Conceivably, the use of selective PI3K isoform inhibi-
tors could be associated with less undesirable side effects 
than the use of broad spectrum PI3K inhibitors [111]. For 
example, it is established that insulin control of glucose 
homeostasis is mainly mediated through p110α PI3K [112] 
and, to a much lower extent, by p110β PI3K [113]. 
Akt inhibitors
Perifosine  is  a  zwitterionic,  water  soluble,  synthetic 
alkylphosphocholine with oral bioavailability that inhibits 
Akt phosphorylation through interaction with the Akt PH 
domain, resulting in disruption of its membrane targeting. 
Interestingly, recent evidence has documented that perifos-
ine targets both mTORC1 and mTORC2 activity by down-
regulating  the  levels  of  mTOR,  raptor,  rictor,  p70S6K, 
and 4E-BP1, owing to their enhanced degradation [114]. 
Perifosine reduced cell proliferation and induced apoptosis 
accompanied by Akt dephosphorylation in a wide variety 
of neoplasias, including AML [115]. Perifosine synergized 
with etoposide in AML blasts, and reduced the clonogenic 
activity of CD34+ cells from leukemic patients, but not from 
healthy  donors  [116].  Moreover,  perifosine  synergized 
with histone deacetylase inhibitors [117] or pro-apoptotic 
TRAIL (TNF-related Apoptosis Inducing Ligand) in AML 
cell lines and primary cells displaying Akt constitutive acti-
vation [118]. However, perifosine also targeted the MER/
ERK 1/2 pro-survival pathway and activated pro-apoptotic 
JNK, [116-120] therefore it could not be considered spe-
cific for the Akt pathway. A phase 1 clinical trial combining 
perifosine and UCN-01 (a staurosporine derivative which 
inhibits  PDK1)  (NCT00301938)  and  a  phase  II  clinical 
trial with perifosine alone (NCT00391560) have been per-
formed in patients with refractory/relapsed AML, but the 
results have not yet been disclosed. 
Akt-I-1/2, a synthetic reversible allosteric inhibitor, is 
an Akt1/Akt2 isoform-specific inhibitor that forms a PH 
domain-dependent  inactive  conformation  with Akt1  and 
Akt2 [121]. Akt-I-1/2 inhibited cell proliferation and clo-
nogenic properties, and induced apoptosis in AML cells 
with  high-risk  cytogenetic  changes/abnormalities  [70]. 
However, it is at present unknown which Akt isoforms are 
expressed by AML blasts.
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mTOR inhibitors
mTOR inhibitors are by far the most developed class 
of compounds which target the PI3K/Akt/mTOR pathway. 
They include: rapamycin (sirolimus, a macrolide derived 
from the bacterium Streptomyces hygroscopicus, originally 
discovered in a soil sample collected on Easter Island) and 
its derivatives CCI-779 (temsirolimus), RAD001 (evero-
limus), and AP23573 (deforolimus) [122]. Temsirolimus 
was  approved  by  US  Food  and  Drug Administration  in 
2007 for the first-line treatment of poor prognosis patients 
with advanced renal cell carcinoma. The overall survival of 
treated patients was increased by nearly 50% (~ 3 months) 
relative to the control group [123]. Some clinical benefits of 
rapamycin/rapalogs have been reported also against endo-
metrial carcinoma and mantle cell lymphoma, however, the 
overall objective response rates in major solid tumors have 
been modest [124].
Rapamycin and rapalogs do not target the catalytic site 
of  mTORC1,  but  rather  bind  its  immunophilin,  FK506 
binding protein 12 (FKBP12) (Figure 2). The rapamycin/
FKBP12 complex then binds mTORC1 and inhibits down-
stream signaling events [125]. Thus, rapamycin and rapa-
logs act as allosteric mTORC1 inhibitors. Recent evidence 
has documented that complex formation with FKBP12 is 
not an absolute requirement for repression of mTORC1 
activity by rapamycin/rapalogs, however, in the absence 
of FKBP12, the drugs display a 100 to 1000-fold lower 
potency than in the presence of the immunophilin [126]. 
Available  data  suggest  that  rapamycin  treatment,  over 
long time periods, also targets mTORC2 [127]. Accord-
ingly, both CCI-779 and RAD001 (10-20 nM) inhibited 
Akt phosphorylation on Ser473 in AML cells in vitro and 
in patients in vivo after a 24 h incubation, through suppres-
sion of the mTORC2 assembly [128]. In contrast, it has 
been documented that RAD001 (10 nM for 24 h) increased 
Akt phosphorylation in vitro on Ser473 in AML samples 
displaying constitutive PI3K/Akt activation [55]. Since a 
neutralizing monoclonal antibody to the IGF-1R α-subunit, 
reversed the RAD001-induced increase of Akt phosphory-
lation and RAD001 treatment led to a significant increase 
in IRS2 protein expression, it was concluded that p-Akt up-
regulation could be explained by the existence of an IGF-1/
IGF-1R autocrine loop, as well as by increased expression 
of IRS2. At present, it is not easy to reconcile these contra-
dictory findings. 
Rapamycin had only a modest effect on primary AML 
cell survival in liquid culture, however, it markedly down-
regulated AML blast clonogenicity while sparing normal 
hematopoietic precursors [129]. Accordingly, others have 
reported that rapamycin led to only a slight decrease in 
AML blast survival in short term cultures, whereas in long 
term cultures the effect was more pronounced [105]. These 
results suggested that the target of rapamycin is the prolif-
erating contingent of the leukemic clone, rather than the 
bulk of AML blasts which are predominantly blocked in the 
G0/G1 phase of the cell cycle. 
However,  rapamycin  cytotoxicity  in  short  term  cul-
tures could be dramatically increased by co-treatment with 
etoposide. Importantly, etoposide toxicity on CD34+ cells 
from healthy donors was not enhanced by addition of rapa-
mycin. Of note, co-incubation with rapamycin enhanced 
etoposide-mediated decrease in the engraftment of AML 
cells in NOD/SCID mice, suggesting the drugs also tar-
geted putative LCSs [105]. 
The rapalog RAD001 synergized with both ATRA and 
histone acetylase inhibitors in inducing growth arrest and 
differentiation of APL cell lines [130, 131].
A few phase I/II clinical trials with rapamycin and rapa-
logs have been performed in patients with relapsed/refrac-
tory AML. Rapamycin induced a partial response in 4 of 9 
adult patients with de novo or secondary AML, who dis-
played activation of mTORC1 signaling, as documented by 
increased levels of p-p70S6K and p-4E-BP1 [129]. RAD001 
has been evaluated in a phase I clinical trial in patients with 
relapsed/refractory  hematologic  malignancies,  including 
AML [132]. However, no AML patients achieved a com-
plete or even partial response. AP23573 has been tested in 
a phase II study in 22 patients with AML [133]. Only one 
patient displayed an objective hematological improvement, 
consisting  of  normalization  of  neutrophils. A  significant 
reduction in mTORC1 activity was observed in response 
to the drug, as documented by decreased p-4E-BP1 levels. 
A recent phase I study in which rapamycin was combined 
with MEC (mitoxantrone, etoposide, cytarabine) polyche-
motherapy  failed  to  demonstrate  any  synergistic  effect 
of the combination in relapsed/refractory AML patients, 
even if proof of rapamycin biological activity in vivo was 
detected, consisting in the dephosphorylation of p70S6K 
[134]. Several clinical trials with rapamycin/rapalogs com-
bined with chemotherapeutic agents are now underway in 
AML patients [135].
Moreover,  a  phase  I  study  has  recently  documented 
the efficacy, in elderly AML patients, of the combination 
etoposide  and  tipifarnib  (R11577,  an  FTI).  Intriguingly, 
the effect of tipifarnib was not always related to Ras inhi-
bition, but rather to inhibition of Rheb farnesylation and, 
consequently, of mTORC1 signaling, as documented by 
decreased levels of p-p70S6K and of its substrate, p-S6 
[136]. 
Dual PI3K/mTOR inhibitors
The rationale for using dual PI3K/mTOR inhibitors is 
that mTORC1 allosteric inhibitors, such as rapamycin/rap-
alogues, could hyperactivate Akt through p70S6K/PI3K, 
as  discussed  earlier  in  this  review.  Moreover,  it  is  now 
emerging that rapamycin/rapalogs have only modest effi-
cacy on total translation rates, and the effects are cell-type 
specific. In contrast, small molecules designed for inhibit-
ing the catalytic site of mTOR, were much more effective 
in this respect, especially in cancer cells [137-141]. Such 
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a phenomenon has been recently reported to occur also in 
AML cells, where rapamycin was unable to block protein 
synthesis, owing to a failure in inducing 4E-BP1 dephos-
phorylation  [142].  Furthermore,  in  some  AML  cases, 
mTORC1 activity does not seem to be under the control of 
PI3K/Akt, despite concomitant PI3K/Akt activation [103]. 
Therefore, the use of a single inhibitor which targets both 
PI3K and mTORC1 catalytic sites could present substantial 
advantages over drugs which only target either PI3K/Akt 
or mTORC1. PI-103 is a pyridonylfuranopyrimidine class 
synthetic molecule that represses the activity of both class 
IA and IB PI3Ks, as well as of mTORC1/mTORC2 [143, 
144]. Two papers have documented the efficacy of PI-103 
in pre-clinical settings of AML. It has been reported that 
PI-103, which itself displayed only modest pro-apoptotic 
activity,  acted  synergistically  with  Nutlin-3  (an  MDM2 
inhibitor) [145, 146], to induce apoptosis in a wild-type 
p53-dependent fashion in AML cell lines and primary cells 
[147]. Another group demonstrated that PI-103 was mainly 
cytostatic for AML cell lines. However, in AML blast cells, 
PI-103 inhibited leukemic proliferation and CFU-L clono-
genicity, induced mitochondrial apoptosis, and synergized 
with etoposide [148]. Of note, PI-103 was not apoptogenic 
in CD34+ cells from healthy donors and had only moder-
ate effects on their clonogenic and proliferative activities. 
Since either RAD001 or IC87114 did not induce apoptosis 
in AML primary cells, it was concluded that dual-targeted 
therapy against PI3K/Akt and mTOR with PI-103 may be 
of therapeutic value in AML [148]. 
Nevertheless, it is conceivable that the new frontier in 
mTOR inhibition will be represented by the second gen-
eration,  ATP-competitive  mTOR  inhibitors  which  bind 
the active site of both mTORC1 and mTORC2 [137-140]. 
These drugs target mTOR signaling functions in a global 
way, so that they are expected to yield a deeper and broader 
antitumor response in the clinic. However, global inhibi-
tion of mTOR is expected to be accompanied by greater 
toxicity to normal cells [149].
CONCLUSIONS
In this review, we have documented that the PI3K/Akt/
mTOR pathway influences proliferation, survival, and drug 
resistance  of AML  cells.  However,  there  still  are  many 
unresolved problems regarding the relevance of PI3K/Akt/
mTOR pathway up-regulation and its druggability in AML 
patients. We have a very limited knowledge of the down-
stream  targets  (genes/proteins)  of  this  pathway  in AML 
cells. Therefore, more detailed investigations of these tar-
gets are highly desirable. Indeed, data emerging from gene 
expression and proteome/phosphoproteome analysis could 
pave the way for functional studies which could then pro-
vide valuable information for improving future therapeutic 
strategies. At present, we do not know what is the most 
effective target in the pathway, and whether combinations 
of horizontal or vertical blockade of the signaling cascade 
may be more effective than blocking at a single node [150].
As with all molecularly targeted approaches, pharma-
codynamic  markers  are  necessary  to  direct  therapeutic 
development of PI3K/Akt/mTOR inhibitors. Hence, clini-
cal trials should examine the inhibitor effects on PI3K/Akt/
mTOR targets to establish the best predictor of response 
[151]. However, no predictive markers for AML patients 
with a high probability of responding to PI3K/Akt/mTOR 
inhibition, or biomarkers of dose/efficacy, have been vali-
dated.  Quantitative  flow  cytometry  appears  particularly 
well suited for this kind of analysis, because it offers obvi-
ous  advantages  over  other  techniques  (western  blot,  for 
example), including quickness, a much lower number of 
cells required to perform the assay, and the possibility of 
identifying different subclones in the leukemic population 
by co-immunostaining with multiple antibodies to surface 
antigens. Accordingly, flow cytometry is rapidly becoming 
the choice analytical technique to study PI3K/Akt/mTOR 
pathway activation in AML patients [70, 133, 152, 153]. 
Another promising quantitative technique requiring a lim-
ited number of cells, which has been already applied to the 
study of AML patients samples, is represented by reverse-
phase protein arrays [74].
It is highly unlikely that inhibition of a single signal-
ing pathway will achieve long-lasting remissions or cure in 
AML, especially for refractory/relapsed patients. However, 
combining PI3K/Akt/mTOR inhibitors with conventional 
chemotherapy drugs, differentiation inducers (ATRA and/or 
arsenic trioxide), or innovative (e.g. TRAIL) agents could 
be a very effective therapeutic option for AML patients, as 
indicated by results obtained in pre-clinical settings. 
The spectacular effect of Bcr-Abl tyrosine kinase inhib-
itors, such as imatinib for the treatment of chronic myelog-
enous leukemia (CML) patients in the chronic phase of the 
disease [154], has fed optimism that modulators of signal 
transduction networks might be very effective also in other 
types of cancer. However, clinical trials performed with 
small molecules targeting the PI3K/Akt/mTOR pathway 
have mostly given a disappointing outcome. This fact has 
led to the suggestion that imatinib success in CML may be 
the exception and not the rule, because imatinib is one of 
the few examples of a drug targeting the anomaly which 
constitutes the underlying pathologic event in the forma-
tion of the disorder [155]. Human cancers are known to 
evolve through a multistage process which can extend over 
a  period  of  several  years. Therefore,  they  progressively 
accumulate mutations and epigenetic anomalies in expres-
sion of multiple genes [156]. As a consequence, neoplastic 
disorders  are  characterized  by  multiple  signaling  abnor-
malities and the deregulated pathways are extremely redun-
dant. Furthermore, the hierarchy of anomalies has not been 
established in many tumors. Therefore, it could be very dif-
ficult to find the right target or combinations of target. 
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AML is no exception to this rule. However, the continu-
ous development of molecularly targeted drugs displaying 
higher  selectivity,  coupled  with  additional  mechanistic 
studies and advances in profiling the signaling networks of 
cancer cells, should make it possible to exploit deregulation 
of the PI3K/Akt/mTOR cascade to achieve more effective 
and less toxic therapies for AML. 
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